Garrison and colleagues also examined the clinical and economic consequences of inaccurate HER2 testing on US patients with early-stage breast cancer and found that incorrect HER2 testing may contribute to total societal loss of up to $1 billion among a cohort of 12,025 misclassified patients [36]. This evidence concerns the gene ERBB2 and breast carcinoma.